This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, R. J. Articles by Fong, Y. Search for Related Content PubMed PubMed Citation Articles by Wong, R. J. Articles by Fong, Y.

Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12

¹Head and Neck Service, Laboratory of Epithelial Cancer Biology,² Hepatobiliary Service, and³ Departments of Surgery and⁴ Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, and⁵ MediGene Inc., San Diego, California

Purpose: There currently is no therapy that enhances the survival of patients with distantly metastatic squamous cell carcinoma (SCC). Engineered herpes oncolytic viruses are effective therapeutic agents when delivered directly to tumors in animal models, but their efficacy in treating disseminated disease is poorly defined.

Experimental Design: We treated disseminated pulmonary SCC in mice with an interleukin (IL)-12-expressing oncolytic herpes virus (NV1042) or with the parent oncolytic virus (NV1023, IL-12 deficient) by i.v. tail vein administration.

Results: Lung IL-12 was 16.1 pg/mg and IFN- was 4.3 pg/mg at day 1 after a single dose of NV1042 (5 x 10⁷ plaque-forming units); levels of both were undetectable for NV1023. 5-Bromo-4-chloro-3-indolyl-ß-D-galactopyranoside histochemistry demonstrated viral infection of disseminated pulmonary tumor nodules by both vectors at day 1, with sparing of adjacent alveolar cells. NV1042-treated lungs showed no surface nodules at day 12, in contrast to NV1023-treated (92 ± 27 surface nodules) and PBS-treated (225 ± 9 surface nodules) lungs. Significantly enhanced survival was observed in NV1042-treated animals compared with NV1023- and PBS-treated animals (log rank < 0.05). In animals with a low tumor burden, 100% of NV1042-treated, 70% of NV1023-treated, and none of the control animals achieved long-term survival. NV1042 efficacy was similar to NV1023 efficacy in animals depleted of CD4/CD8 T lymphocytes, showing that IL-12 expression enhances oncolytic activity through immune effects. Histology showed no cytopathic effects in non-tumor-bearing lung, brain, spleen, liver, and pancreas after completion of viral therapy. No animals demonstrated any visible side effects attributable to viral therapy.

Conclusions: The i.v. delivery of an oncolytic herpes virus may achieve effective infection, oncolysis, and transgene expression at distant tumor sites. This approach to systemic therapy combining oncolysis with IL-12 immune stimulation led to significantly improved survival in animals with disseminated SCC.

This article has been cited by other articles:

				Z. Yu, S. Li, Y.-Y. Huang, S.-F. Lin, Y. Fong, and R. J. Wong Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy Clin. Cancer Res., March 15, 2008; 14(6): 1897 - 1904. [Abstract] [Full Text] [PDF]

				M. M. Stanford, J. W. Barrett, P.-A. Gilbert, R. Bankert, and G. McFadden Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits J. Virol., November 15, 2007; 81(22): 12704 - 12708. [Abstract] [Full Text] [PDF]

				S. Varghese, S. D. Rabkin, G. P. Nielsen, U. MacGarvey, R. Liu, and R. L. Martuza Systemic Therapy of Spontaneous Prostate Cancer in Transgenic Mice with Oncolytic Herpes Simplex Viruses Cancer Res., October 1, 2007; 67(19): 9371 - 9379. [Abstract] [Full Text] [PDF]

				J. Veerapong, K. A. Bickenbach, M. Y. Shao, K. D. Smith, M. C. Posner, B. Roizman, and R. R. Weichselbaum Systemic Delivery of {gamma}134.5-Deleted Herpes Simplex Virus-1 Selectively Targets and Treats Distant Human Xenograft Tumors That Express High MEK Activity Cancer Res., September 1, 2007; 67(17): 8301 - 8306. [Abstract] [Full Text] [PDF]

				Y.-Y. Huang, Z. Yu, S.-F. Lin, S. Li, Y. Fong, and R. J. Wong Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1965 - 1970. [Abstract] [Full Text] [PDF]

				S. Varghese, S. D. Rabkin, P. G. Nielsen, W. Wang, and R. L. Martuza Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin. Cancer Res., May 1, 2006; 12(9): 2919 - 2927. [Abstract] [Full Text] [PDF]

				Z. Yu, M.-K. Chan, P. O-charoenrat, D. P. Eisenberg, J. P. Shah, B. Singh, Y. Fong, and R. J. Wong Enhanced Nectin-1 Expression and Herpes Oncolytic Sensitivity in Highly Migratory and Invasive Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4889 - 4897. [Abstract] [Full Text] [PDF]

				R. J. Wong, M.-K. Chan, Z. Yu, R. A. Ghossein, I. Ngai, P. S. Adusumilli, B. M. Stiles, J. P. Shah, B. Singh, and Y. Fong Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12 Clin. Cancer Res., July 1, 2004; 10(13): 4509 - 4516. [Abstract] [Full Text] [PDF]